(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/240825 A1

(51) International Patent Classification:
A61K 31/5025 (2006.01) *C07D 403/12* (2006.01)
C07D 495/04 (2006.01)

(21) International Application Number:
PCT/US2022/028511

(22) International Filing Date:
10 May 2022 (10.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/186,550 10 May 2021 (10.05.2021) US
63/325,716 31 March 2022 (31.03.2022) US

(71) Applicant: **FOGHORN THERAPEUTICS INC.** [US/US]; 500 Technology Square, Suite 700, Cambridge, MA 02139 (US).

(72) Inventors: **NETHERTON, Matthew**; c/o Foghorn Therapeutics Inc., 500 Technology Square, Suite 700, Cambridge, MA 02139 (US). **BRUCELLE, Francois**; c/o Foghorn Therapeutics Inc., 500 Technology Square, Suite 700, Cambridge, MA 02139 (US). **DENG, Jing**; c/o Foghorn Therapeutics Inc., 500 Technology Square, Suite 700, Cambridge, MA 02139 (US). **VOIGT, Johannes, H.**; c/o Foghorn Therapeutics Inc., 500 Technology Square, Suite 700, Cambridge, MA 02139 (US). **WILSON, Kevin, J.**; c/o Foghorn Therapeutics Inc., 500 Technology Square, Suite 700, Cambridge, MA 02139 (US).

(74) Agent: **CRAWFORD, Bradley W.**; Eli Lilly And Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/240825 A1

(54) Title: COMPOUNDS AND USES THEREOF

(57) Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.